Laboratory Corporation of... (LH)
217.12
-3.45 (-1.56%)
At close: Apr 17, 2025, 3:59 PM
217.46
0.16%
After-hours: Apr 17, 2025, 08:00 PM EDT
Laboratory of America Revenue Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LabCorp Diagnostics Revenue | 2.55B | 2.52B | 2.48B | 9.42B | 2.34B | 2.34B | 2.38B | 9.2B | 1.41B | 1.45B | 1.46B | 10.36B | 1.46B | 1.5B | 1.44B | 9.25B | 1.24B | 1.09B | 1.14B | 2.34B | 1.18B | 1.13B | 1.07B | 2.19B | 1.08B | 1.05B | 1.08B | 6.07B | 761.1M | 699.7M | 690.3M | 5.69B | 701.1M | 722.4M | 704.6M | 4.61B | 2.28B | 1.59B | 300.3M | 5.68B | 1.47B | 1.43B | 1.35B | 5.47B | 1.38B | 1.38B |
| LabCorp Diagnostics Revenue Growth | +1.13% | +1.82% | -73.66% | +301.55% | +0.17% | -1.76% | -74.11% | +554.68% | -3.18% | -0.51% | -85.92% | +610.08% | -2.39% | +3.96% | -84.46% | +645.10% | +13.55% | -4.38% | -51.16% | +99.23% | +4.36% | +4.80% | -50.92% | +102.47% | +2.59% | -2.25% | -82.25% | +698.11% | +8.78% | +1.36% | -87.86% | +711.33% | -2.95% | +2.53% | -84.73% | +102.14% | +43.73% | +428.70% | -94.72% | +286.83% | +2.63% | +6.00% | -75.29% | +296.66% | -0.28% | n/a |
| Covance Drug Development Revenue | 737.7M | 707M | 710.9M | 2.77B | 719.1M | 699M | 1.4B | 5.71B | 2.21B | 2.26B | 2.45B | 5.85B | 2.62B | 2.37B | 2.76B | 4.88B | 2.7B | 1.69B | 1.7B | 6.66B | 1.76B | 1.76B | 1.72B | 6.66B | 1.75B | 1.81B | 1.77B | 14.34B | 1.84B | 1.8B | 1.72B | 13.19B | 1.67B | 1.66B | 1.59B | 12.4B | 6.25B | 4.62B | 1.47B | 329.4M | 82.9M | 85.1M | 80.4M | 343.1M | 81.7M | n/a |
| Covance Drug Development Revenue Growth | +4.34% | -0.55% | -74.37% | +285.79% | +2.88% | -50.12% | -75.46% | +158.66% | -2.12% | -8.10% | -58.02% | +123.32% | +10.65% | -14.23% | -43.46% | +80.37% | +59.76% | -0.55% | -74.45% | +278.73% | -0.10% | +2.26% | -74.16% | +280.38% | -3.42% | +2.47% | -87.66% | +680.59% | +2.12% | +4.73% | -86.97% | +688.84% | +0.73% | +4.34% | -87.17% | +98.42% | +35.20% | +213.99% | +346.87% | +297.35% | -2.59% | +5.85% | -76.57% | +319.95% | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|
| Europe Revenue | 2.05B | 1.51B | 1.2B | 1.18B | 857.7M |
| Europe Revenue Growth | +35.62% | +26.05% | +1.55% | +37.74% | n/a |
| North America Revenue | 13.09B | 11.53B | n/a | n/a | n/a |
| North America Revenue Growth | +13.61% | n/a | n/a | n/a | n/a |
| Other Countries Revenue | 976.4M | 941M | n/a | n/a | n/a |
| Other Countries Revenue Growth | +3.76% | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 595.2M | 568.6M | 557.8M | 508.4M | 532.9M | 525.5M | 505.8M | 553.6M | 536.5M | 510M | 486M | 464.1M | 543.7M | 519.9M | 458.7M | 429.8M | 518M | 419.5M | 396.3M | 395.5M | 413.9M | 401.5M | 415.3M | 393.8M | 396.9M | 381.8M | 395.2M | 397M | 492.4M | 465.3M | 435.3M | 419.4M | 406M | 400.5M | 408M | 411.9M | 404.9M | 382.5M | 392.4M | 415.1M |
| Selling, General, and Administrative Revenue Growth | +4.68% | +1.94% | +9.72% | -4.60% | +1.41% | +3.89% | -8.63% | +3.19% | +5.20% | +4.94% | +4.72% | -14.64% | +4.58% | +13.34% | +6.72% | -17.03% | +23.48% | +5.85% | +0.20% | -4.45% | +3.09% | -3.32% | +5.46% | -0.78% | +3.95% | -3.39% | -0.45% | -19.37% | +5.82% | +6.89% | +3.79% | +3.30% | +1.37% | -1.84% | -0.95% | +1.73% | +5.86% | -2.52% | -5.47% | n/a |
| Research and Development Revenue | n/a | n/a | n/a | n/a | 2M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Research and Development Revenue Growth | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |